John Libbey Eurotext

Chronic lymphocytic leukaemia and Waldenström’s macroglobulinemia (3rd Edition)

Leucémie lymphoïde chronique et macroglobulinémie de Waldenström (3e édition)

Alain Delmer, Pierre Feugier

Collection : Collection FMC de la revue Hématologie
180 pages
Published in : French
Speciality : Medical Biology and Physiology   Hematology  
Format : 17 X 24

Print 36.00 €
ISBN : 978-2-7420-1490-3
Available Ajouter au panier

Lymphoid blood diseases of the elderly, often slow-progressing diseases where one can only wait and see, sometimes very aggressive forms where unfortunately therapeutic means are extremely limited, old clichés die hard; chronic lymphocytic leukaemia and Waldenström’s disease have long been considered the poor relations of haematology.

Over the last twenty years, the approach to these two diseases has changed both biologically and therapeutically and this new monograph is proof of that change.

From the description of new mutations and the activation pathways involved to the role played by the microenvironment, or the importance of achieving undetectable residual disease and the contribution in terms of survival of monoclonal antibodies, and more recently the new BCR- and apoptosis-targeted therapies, the progress has been immense and has opened up new horizons.

By bringing together the different French specialists in these blood diseases, the objective here is to propose a summary of the subject, offering specialists and non-specialists an information update and the desire to learn more if required.



• Epidemiology of CLL and Waldenström’s macroglobulinemia
• Cytological and immunophenotypic diagnosis and B-cell chronic lymphoproliferative disorders
• Cytogenetic and genetic aspects
• New genomic alterations and clonal evolution
• B cell antigen receptor signalling and role of the microenvironment
• Monoclonal B lymphocytosis
• Prognostic factors
• Minimal residual illness: what’s new?
• Stage A chronic lymphocytic leukaemia according to the Binet classification
• First-line treatment of so-called fit subjects
• First-line treatment of so-called unfit subjects
• New medications
• Relapse management
• Cell therapy
• Infections
• Autoimmunity
• Richter syndrome
• Biological advances
• Therapeutic approach